Atopic dermatitis and risk of atrial fibrillation or flutter: a 35-year follow-up study

Atopic Dermatitis

Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis

J Am Acad Dermatol.

Thyssen JP, Toft PB, Halling-Overgaard AS, Gislason GH, Skov L, Egeberg A

doi: 10.1016/j.jaad.2017.03.003.

Atopic Dermatitis

Factors associated with improvement of quality of life among parents of children with atopic dermatitis: one-year prospective cohort study

J Eur Acad Dermatol Venereol.

Maksimovic N, Zaric M, Reljic V, Nikolic M, Gazibara T

doi: 10.1111/jdv.15939.

Atopic Dermatitis

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Br J Dermatol

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A

doi: 10.1111/bjd.19460

Atopic Dermatitis

Increased risk of cutaneous and systemic infections in atopic dermatitis - A cohort study.

J Invest Dermatol.

Langan SM, Abuabara K, Henrickson SE, Hoffstad O, Margolis DJ

doi: 10.1016/j.jid.2017.01.030.

Atopic Dermatitis

Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies

Br J Dermatol

Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JP01, JP02 Study Group.

doi: 10.1111/bjd.20873

Further Publications Dermatology

Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial

Lancet

Svendsen JH, Diederichsen SZ, Højberg S, Krieger DW, Graff C, Kronborg C, Olesen MS, Nielsen JB, Holst AG, Brandes A, Haugan KJ, Køber L

doi: 10.1016/S0140-6736(21)01698-6

Atopic Dermatitis

Risk of systemic infections in adults with atopic dermatitis: a nationwide cohort study

J Am Acad Dermatol.

Droitcourt C, Vittrup I, Kerbrat S, Egeberg A, Thyssen JP

doi: 10.1016/j.jaad.2020.07.111.

Atopic Dermatitis

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Br J Dermatol.

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A

doi: 10.1111/bjd.19460.

Atopic DermatitisAllergic Diseases

Allergic Contact Dermatitis in Atopic Individuals: Results of a 30-year Retrospective Study

Contact Dermatitis.

Teo Y, McFadden JP, White IR, Lynch M, Banerjee P

doi: 10.1111/cod.13363.

Related content

Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis

Factors associated with improvement of quality of life among parents of children with atopic dermatitis: one-year prospective cohort study

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Increased risk of cutaneous and systemic infections in atopic dermatitis - A cohort study.

Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies

Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial

Risk of systemic infections in adults with atopic dermatitis: a nationwide cohort study

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Allergic Contact Dermatitis in Atopic Individuals: Results of a 30-year Retrospective Study